Hormone Replacement Therapy

  • Elisabeth von der Lohe


Coronary heart disease continues to be an infrequent disease in premenopausal women, even in women with diabetes mellitus; however, after menopause (the time when estrogen production decreases) the prevalence of coronary heart disease in women increases with increasing age and reaches that of men by age 75 years. Women with premature menopause (<35 years of age) regardless of etiology (either natural or after ovariectomy) have a twofold higher risk of coronary heart disease (Wenger et al. 1993). These findings led to the conclusion that estrogens are cardioprotective and play a major role for the low prevalence of cardiovascular disease in pre-menopausal women; however, the role of estrogen (and other hormones) in the pathogenesis of coronary heart disease is still under investigation.


Coronary Heart Disease Estrogen Replacement Therapy Coronary Heart Disease Event Medroxyprogesterone Acetate Secondary Prevention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barrett-Connor E, Bush TL (1991) Estrogen and coronary heart disease in women. JAMA 265:1861–1867PubMedCrossRefGoogle Scholar
  2. Barrett-Connor E, Grady D, Sashegyi A et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 287:847–857CrossRefGoogle Scholar
  3. Bergkvist L, Adami HO, Persson I et al. (1989) Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progesterone replacement therapy. AM J Epidemiol 130:221–228PubMedGoogle Scholar
  4. Blumenthal RS, Zacur HA, Reis SE, Post WS (2000) Beyond the null hypothesis - Do the HERS results disprove the estrogen/coronary heart disease hypothesis? Am J Cardiol 85:1015–1017PubMedCrossRefGoogle Scholar
  5. Brett KM, Madans JH (1995) Long-term survival after coronary heart disease: comparisons between men and women in a national sample. Ann Epidemiol 5:25–32PubMedCrossRefGoogle Scholar
  6. Bush TL (1991) Long-term effect of estrogen use on cardiovascular death in women. AHA Meeting, November 1991, Orlando/FLGoogle Scholar
  7. Bush TL, Barrett-Connor E, Cowan LD et al. (1987) Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinics Program follow-up study. Circulation 75:1102–1109PubMedCrossRefGoogle Scholar
  8. Chen CL, Weiss NS, Newcomb P et al. (2002) Hormone replacement therapy in relation to breast cancer. J Am Med Assoc 287:734–741CrossRefGoogle Scholar
  9. Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589PubMedCrossRefGoogle Scholar
  10. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidermiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047–1059CrossRefGoogle Scholar
  11. Collins P, Rosana G, Sarrel PM et al. (1995) Estrogen attenuates acetylcholine-induced coronary arterial constriction in women but not in men with coronary heart disease. Circulation 92:24–30PubMedCrossRefGoogle Scholar
  12. Criqui MH, Suwarez L, Barrett-Connor E et al. (1988) Postmenopausal estrogen use and mortality. Am J Epidemiol 128:606–614PubMedGoogle Scholar
  13. Cummings SR, Eckert S, Krueger KA et al. (1999) The effect of raloxifene on the risk of breast cancer in post-menopausal women: Results from the MORE (Multiple Outcomes of Raloxifene Evaluation) trial. JAMA 281:2189PubMedCrossRefGoogle Scholar
  14. Cushman M, Legault C, Barrett-Connor E et al. (1999) Effect of postmenopausal hormones on inflammation-sensitive proteins: The postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 100:717PubMedCrossRefGoogle Scholar
  15. Daly E, Vessey MP, Hawkins MM et al. (1996) Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977PubMedCrossRefGoogle Scholar
  16. Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67–72PubMedCrossRefGoogle Scholar
  17. Fleming KC (1999) Hormone replacement therapy: practical prescribing. In: Charney P (ed) Coronary artery disease in women. American College of Physicians, Philadelphia, p 294Google Scholar
  18. Folsom AR, Mink PJ, Sellers TA et al. (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of post-menopausal women. Am J Publ Health 85:1128–1132CrossRefGoogle Scholar
  19. Fletcher SW, Colditz GA (2002) Failure of estrogen plus progestin therapy for prevention. J Am Med Assoc 288:366–368CrossRefGoogle Scholar
  20. Folsom AR, Mink PJ, Sellers TA et al. (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Publ Health 85:1128–1132CrossRefGoogle Scholar
  21. Gerhard M, Ganz M (1995) How do we explain the clinical benefits of estrogen? Circulation 92:5PubMedCrossRefGoogle Scholar
  22. Gilligan DM, Quyyumi AA, Connon RO III (1994) Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89:2541–2551CrossRefGoogle Scholar
  23. Grady D, Rubin SM, Petitti DB et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016–1037PubMedGoogle Scholar
  24. Grady G, Gebretsadik T, Kerlikowske K et al. (1995) Hormone replacement therapy and endometrial cancer risk; A meta-analysis. Obstet Gynecol 85:304–313PubMedCrossRefGoogle Scholar
  25. Grady D, Hulley SB, Furberg C (1997) Venous thromboembolic events associated with hormone replacement therapy. JAMA 278:477PubMedCrossRefGoogle Scholar
  26. Grady D, Wenger NK, Herrington D et al. (2000) Postmenopausal hormone therapy increases risk for venous thrombembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 132:689–696PubMedGoogle Scholar
  27. Grady D, Herrington D, Bittner V et al. for the HERS RESEARCH GROUP (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). J Am Med Assoc 288:49–57CrossRefGoogle Scholar
  28. Grady D, Wenger NK, Herrington D et al. (2000) Postmenopausal hormone therapy increases risk for venous thrombembolic disease:the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132:689–696PubMedGoogle Scholar
  29. Grodstein F, Stampfer MJ, Goldhaber SZ et al. (1996a) Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348:983CrossRefGoogle Scholar
  30. Grodstein F, Stampfer MJ, Manson JE et al. (1996b) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 332:1589Google Scholar
  31. Grodstein F, Stampfer MJ, Colditz GA et al.(1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769PubMedCrossRefGoogle Scholar
  32. Grodstein F, Manson JE, Stampfer MJ et al. (1999) Postmenopausal hormones and recurrence of coronary events in the Nurses’ Health Study (abstract). Circulation 100: I-871Google Scholar
  33. Henderson BE, Paganini-Hill A, Ross RK. (1988) Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 159:312–317PubMedGoogle Scholar
  34. Henderson BE, Paganini-Hill A, Ross RK (1999) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75–78CrossRefGoogle Scholar
  35. Herrington DM (1999) The HERS trial results: Paradigms lost? Ann Intern Med 131:463PubMedGoogle Scholar
  36. Herrington DM, Beboussin KB, Brosnihan KB et al. (2000) Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343:522–529PubMedCrossRefGoogle Scholar
  37. Herrington DM (2001) What about estrogens now? Curr J Rev 10 (2)]Google Scholar
  38. Hulley S, Grady D, Bush T et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613PubMedCrossRefGoogle Scholar
  39. Jick H, Derby LE, Myers MW et al. (1996) Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981PubMedCrossRefGoogle Scholar
  40. Khovidhunkit W, Shoback DM (1999) Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130:431PubMedGoogle Scholar
  41. Lacey JV Jr, Mink PJ, Lubin JH et al. (2002) Menopausal hormone replacement therapy and the risk of ovarian cancer. J Am Med Assoc 288:334–341CrossRefGoogle Scholar
  42. Lobo RA: Hormones, hormone replacement therapy, and heart disease. In Douglas PS (ed): Cardiovascular Health and Disease in Women. Philadelphia, WB Saunders, 1993, p 153Google Scholar
  43. Love RR, Newcomb PA, Wiebe DA et al. (1990) Effects of tamoxifene therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82:1327PubMedCrossRefGoogle Scholar
  44. Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801PubMedCrossRefGoogle Scholar
  45. Miller BA, Ries LAG, Hankey BF et al. (eds) (1992) Cancer Statistics Review: 1973–89. National Cancer Institute,Washington DC, NIH pub no 92, p 2789Google Scholar
  46. Mosca L, Barret-Connor E, Wenger NK et al. (2001) Design and methods of the Raloxifene Use for The Heart (RUTH) Study. Am J Cardiol 88:392–395PubMedCrossRefGoogle Scholar
  47. Nachtigall LE, Nachtigall RH, Nachtigall RD et al. (1979) Estrogen replacement therapy. Part II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74–79PubMedCrossRefGoogle Scholar
  48. Nachtigall M, Smilen SW, Nachtigall RD et al. (1992) Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 80:827–830PubMedGoogle Scholar
  49. Newton KM (1995) Estrogen replacement therapy and prognosis after first myocardial infarction [Abstract]. AHA Meeting, November 1995, San Diego/CAGoogle Scholar
  50. Noller KL (2002) Estrogen replacement therapy and risk of ovarian cancer. J Am Med Assoc 288:368–369CrossRefGoogle Scholar
  51. Pamela S, Douglas PS (2001) Coronary artery disease in women. In: Braunwald E, Zipes DP, Libby P (eds) Heart disease. Saunders, PhiladelphiaGoogle Scholar
  52. Reis SE, Gloth ST, Blumenthal RS et al. (1994) Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 89:52–60PubMedCrossRefGoogle Scholar
  53. Rich-Edwards JW, Manson JE, Hennekens CH et al. (1995) The primary prevention of coronary heart disease in women. N Engl J Med 332:1758–1766PubMedCrossRefGoogle Scholar
  54. Ridker PM, Hennekens CN, Rifai N et al. (1999) Hormone replacement therapy and increased plasma concentration of Creactive protein. Circulation 100:713PubMedCrossRefGoogle Scholar
  55. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J Am Med Assoc 285:1460–1465CrossRefGoogle Scholar
  56. Ross RK, Paganini-Hill A, Wan P, Pike M (2000) Effect of hormone replacement therapy on breast cancer:estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328–332PubMedCrossRefGoogle Scholar
  57. Rutqvist LE, Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifene: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398PubMedCrossRefGoogle Scholar
  58. Sack MN, Rader DJ, Cannon RO III (1994) Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 343:269–270PubMedCrossRefGoogle Scholar
  59. Schairer C, Lubin J, Troisi R et al. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 283:485–491CrossRefGoogle Scholar
  60. Stampfer MJ, Willett WC, Colditz GA et al. (1986) A prospective study of postmenopausal estrogen therapy, and coronary heart disease. N Engl J Med 313:1044–1049CrossRefGoogle Scholar
  61. Stampfer MJ, Colditz GA, Willett WC et al. (1991) Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’ Health study. N Engl J Med 325:756PubMedCrossRefGoogle Scholar
  62. Steinberg KK, Thacker SB, Smith JC (1991) A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985–1990PubMedCrossRefGoogle Scholar
  63. Sullivan JM, Vander Zwaag R, Hughes JP et al. (1990) Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 150:2557–2562PubMedCrossRefGoogle Scholar
  64. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KK (1995) Estrogen replacement therapy after coronary artery bypass surgery: Effect on survival. Circulation 345:669Google Scholar
  65. The American-Canadian Cooperative Study Group (1986) Persantine Aspirin Trial in cerebral ischemia. Part III: Risk factors for stroke. Stroke 17:12–18CrossRefGoogle Scholar
  66. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273:199–208CrossRefGoogle Scholar
  67. Walsh BW, Kuller LH, Wild RA et al. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445PubMedCrossRefGoogle Scholar
  68. Weiner CP, Lizasoain I, Baylis SA et al. (1994) Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci USA 91:5212–5216PubMedCrossRefGoogle Scholar
  69. Wenger NK, Speroff L, Packard B (1993) Cardiovascular health and disease in women. N Engl J Med 329:247–526PubMedCrossRefGoogle Scholar
  70. Wenger NK, Knatterud GL, Canner PL (2000) Early risks of hormone therapy in patients with coronary heart disease. J Am Med Assoc 284:41–43CrossRefGoogle Scholar
  71. WHI (Women’s Health Initiative) HRT Update. Available at:
  72. Williams JK, Adams MR, Herrington DM, Clarkson TB (1992) Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 20:452–457PubMedCrossRefGoogle Scholar
  73. Wilson PWF, Garrison RJ, Castelli WP (1985) Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med 313:1038–1043PubMedCrossRefGoogle Scholar
  74. Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized Controlled Trial. J Am Med Assoc 288:321–333CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Elisabeth von der Lohe
    • 1
  1. 1.Wishard Health Services, Krannert Institute of CardiologyIndiana University, Clarian Cardiovascular CenterIndianapolisUSA

Personalised recommendations